Compile Data Set for Download or QSAR
Report error Found 201 Enz. Inhib. hit(s) with all data for entry = 939
TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM300273(US9593110, 2-11)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 87b | US9593110, Example 88b | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299643(US9593110, Example 13 | (2R,4R)-2-Amino-5-(5′...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM300275(US9593110, 2-12)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM300276(US9593110, 18-10)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 87b | US9593110, Example 88b | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM300277(US9593110, 2-13)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM300278(US9593110, 18-11)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299647(US9593110, Example 15 | (2R,4R)-2-Amino-5-(5′...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM300279(US9593110, 2-14)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 87b | US9593110, Example 88b | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299633(US9593110, Example 8 | (2S,4S)-5-(3′-Chlorob...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299634(US9593110, Example 28 | (2S,4S)-2-(Acetylaminometh...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM300266(US9593110, 2-8)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299635(US9593110, Example 29 | (2R,4R)-5-(5′-Chloro...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM300267(US9593110, 18-6)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299630(US9593110, Example 81 | US9593110, Example 85a | (...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM300268(US9593110, 2-9)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299630(US9593110, Example 81 | US9593110, Example 85a | (...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299630(US9593110, Example 81 | US9593110, Example 85a | (...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299639(US9593110, Example 10 | (2S,4S)-5-Biphenyl-4-yl-2-...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM300271(US9593110, 18-8)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM300272(US9593110, 62)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 87b | US9593110, Example 88b | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 87b | US9593110, Example 88b | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM300292(US9593110, 7-1)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 87b | US9593110, Example 88b | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299662(US9593110, Example 40 | (2R,4R)-2-(4-Aminobutyryla...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM300294(US9593110, 7-2)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299664(US9593110, Example 96b)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM300295(US9593110, 7-3)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM300296(US9593110, 7-4)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 87b | US9593110, Example 88b | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM300281(US9593110, 2-15)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM300282(US9593110, 2-16)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299651(US9593110, Example 33 | (2R,4R)-2-(2-Aminoacetylam...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM300283(US9593110, 21-1)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 87b | US9593110, Example 88b | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM300284(US9593110, 4-1)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 87b | US9593110, Example 88b | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM300286(US9593110, 4-2)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM300287(US9593110, 21-3)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM300288(US9593110, 4-3)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299355(US9593110, Example 61a | US9593110, Example 74 | U...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM300305(US9593110, 7-11)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM300307(US9593110, 9-1)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 87b | US9593110, Example 88b | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM300308(US9593110, 9-2)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM299355(US9593110, Example 61a | US9593110, Example 74 | U...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

TargetNeprilysin(Human)
Theravence Biopharma R&D Ip

US Patent
LigandPNGBDBM300309(US9593110, 30-1)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
US Patent

Displayed 1 to 50 (of 201 total ) | Next | Last >>
Jump to: